ReviewFrontiers in pharmacology2026
15-hydroxyeicosatetraenoic acid (15-HETE)-GPR39 axis: a potential therapeutic target in eosinophilic asthma.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Arachidonic acid (AA) metabolites play key roles in the pathophysiology of asthma. Along with cyclooxygenase and CYP P450, lipoxygenases (LO) produce these metabolites. 15-hydroxyeicosatetraenoic acid (15-HETE), a product of 15-LO, has been implicated in severe asthma, particularly eosinophilic asthma. This article reviews the AA-15-HETE axis in eosinophilic asthma. 15-HETE contributes to key features of eosinophilic asthma, including eosinophil recruitment, mucus hypersecretion, and airway remodeling. Despite these observations, the downstream signaling mechanisms through which 15-HETE exerts its effects remain incompletely understood. GPR39 has recently been proposed as a potential receptor for 15-HETE, linking lipid metabolism to intracellular signaling involved in inflammation and tissue remodeling. Although the role of GPR39 in asthma has not been studied, its ability to respond to bioactive lipids suggests it may serve as a critical signaling node in eosinophilic inflammation. Taken together, these findings support a model in which the AA-15-HETE-GPR39 axis contributes to the pathogenesis of eosinophilic asthma. Targeting GPR39 may therefore represent a novel and underexplored therapeutic strategy for modulating airway inflammation and remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.